iShares Biotechnology ETF (NASDAQ:IBB) Stock Holdings Lowered by Canton Hathaway LLC

Canton Hathaway LLC cut its position in iShares Biotechnology ETF (NASDAQ:IBB) by 1.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,861 shares of the financial services provider’s stock after selling 190 shares during the quarter. Canton Hathaway LLC’s holdings in iShares Biotechnology ETF were worth $1,436,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IBB. Darwin Wealth Management LLC acquired a new stake in shares of iShares Biotechnology ETF in the third quarter valued at approximately $29,000. Highline Wealth Partners LLC acquired a new stake in iShares Biotechnology ETF in the 3rd quarter valued at approximately $30,000. Bbjs Financial Advisors LLC bought a new stake in iShares Biotechnology ETF during the 2nd quarter valued at $31,000. Ashton Thomas Securities LLC acquired a new position in iShares Biotechnology ETF during the 3rd quarter worth $36,000. Finally, Voisard Asset Management Group Inc. bought a new position in shares of iShares Biotechnology ETF in the third quarter worth $59,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

Shares of IBB opened at $139.00 on Monday. iShares Biotechnology ETF has a one year low of $117.28 and a one year high of $150.57. The stock’s fifty day moving average is $143.43 and its 200-day moving average is $141.87.

iShares Biotechnology ETF Dividend Announcement

The business also recently declared a dividend, which was paid on Monday, September 30th. Shareholders of record on Wednesday, September 25th were given a dividend of $0.2005 per share. The ex-dividend date was Wednesday, September 25th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.